Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
J. Clin. Invest. Peter S. Kim, et al. 118:1700 doi:10.1172/JCI34333 [
Go to this article.]
Figure 2Intact 7.16.4 mAb accumulates preferentially within the draining lymph nodes of neu-expressing, GM-CSF–secreting tumor vaccine cells. (
A) Indium-111–labeled intact 7.16.4 mAb forms a hot spot (arrow) at the location of the vaccine.
neu-N mice were given the neu vaccine cells (3T3 neu/GM) (1 × 10
6) in the right leg or the control GM-CSF–secreting vaccine cells (3T3 NP/GM) (1 × 10
6) in the left leg s.c., concurrent with an i.v. injection of indium-111–labeled intact 7.16.4 mAb. The SPECT/CT images, using an XPECT system, were taken at 1, 24, and 48 hours. Three mice per group were analyzed per experiment, and these experiments were repeated once with similar results. (
B) Accumulation of indium-111–labeled intact 7.16.4 mAb at the site of a neu-targeted vaccine and its draining lymph node. Administration of vaccine cells and antibodies was as same as in
A. After 48 hours, VDLNs (left and right inguinal) and superficial cervical lymph nodes (used as a control for the non-draining lymph nodes) were isolated and their radioactivity was measured in a gamma counter. Plotted is the mean radioactivity (injection dose %) for 5 mice per group.
P values comparing right and left inguinal lymph nodes were determined by Mann-Whitney
U test.
